Page 30 - P4403.59-V53_Numark Magazine July 24 FINAL

YOUR QUERIES

ASK Our Information

Services agony
aunt Sue Swift
SUE shares your

recent queries
around The
Drug Tariff.

Remember - Information Services are here to offer a helping hand whenever you need them.
Let us do the work so you can concentrate on helping your team and your patients.

Understanding Generic Alternatives for

Fluticasone/Salmeterol Dry Powder Inhalers

Navigating the variety of inhaler options available for treating asthma and chronic
obstructive pulmonary disease (COPD) can be challenging for both patients and
healthcare providers. When a familiar brand such as Seretide Accuhaler® is out of
stock or a more cost-effective alternative is suggested, questions naturally arise
about the suitability of substitutes like Fusacomb Easyhaler®. This article aims to
clarify the interchangeability of these inhalers, ensuring that you can confidently
make informed decisions about dispensing and using these medications.
Read on to learn about the licensed indications, equivalent brands, shelf lives,
pricing, and practical advice for prescribers and pharmacists.

Q: I have a prescription for Fluticasone propionate
250mcg/dose / Salmeterol 50mcg/dose dry powder
inhaler. We usually supply Seretide Accuhaler® but our
PMR is suggesting a product called Fusacomb Easyhaler®
50/250 dry powder inhaler. Can we supply this one?

A: Yes, you can supply Fusacomb Easyhaler® instead of
Seretide Accuhaler®. Fusacomb Easyhaler® is a generic
fluticasone/salmeterol dry powder inhaler available in the
UK, and it is clinically equivalent to Seretide Accuhaler®.

Licensed Indications

• Asthma: For adults and adolescents 12 years and older who need regular treatment with
a combination of a long-acting beta agonist (LABA) and an inhaled corticosteroid (ICS).
This is suitable for patients not adequately controlled with an ICS and a short-acting
beta agonist (SABA), or those already controlled using a LABA and ICS combination.
• COPD: For adults requiring symptomatic treatment for COPD.

30

12/06/2024 09:32:42
P4403.59-V53_Numark Magazine July 24.indd 30 12/06/2024 09:32:42
P4403.59-V53_Numark Magazine July 24.indd 30